AHB(SH:688639)2024-08-30 07:37Group 1: Financial Performance - The company's revenue for the first half of 2024 reached 1.016 billion CNY, representing a year-on-year growth of 19.57% [2] - The price of valine products has decreased compared to the same period last year due to increased competition, impacting overall profits [2] - The company plans to invest no more than 700 million CNY in projects to expand production capacity for branched-chain amino acids and refined amino acids [4] Group 2: Product Development and Market Expansion - New products such as 1,3-propanediol, succinic acid, and amino acids are being launched as planned, further expanding the company's operational scale [3] - The company has established a strong customer base in various downstream markets, including chemicals, pharmaceuticals, and food additives, for its new products [3] - The company is actively pursuing international market development, enhancing its sales organization and optimizing regional sales management [4] Group 3: Investor Relations and Future Outlook - The company expressed gratitude to investors for their ongoing support and emphasized its commitment to improving management and core competitiveness [5] - The company is progressing with its plans for a public offering to raise 1.689 billion CNY for various projects, including the construction of production bases for bio-based succinic acid and apple acid [4] - The company aims to enhance its market influence and provide more value to global customers through innovative product applications [4]